BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib

Biochemical and Biophysical Research Communications

Volumn 482, Issue 4, 2017, Pages 1491-1497

  Nagasawa, Ikuko ^a,b   Kunimasa, Kazuhiro ^a   Tsukahara, Satomi ^a   Tomida, Akihiro ^a,b  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

ATF4; BRAF; GCN2; Integrated stress response; Vemurafenib

Indexed keywords

AMINO ACID; B RAF KINASE; GENERAL CONTROL NONDEREPRESSIBLE 2 PROTEIN; GLUCOSE REGULATED PROTEIN 78; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE; PROTEIN KINASE R; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VEMURAFENIB; ACTIVATING TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC AGENT; ATF4 PROTEIN, HUMAN; BRAF PROTEIN, HUMAN; EIF2AK3 PROTEIN, HUMAN; EIF2AK4 PROTEIN, HUMAN; HEAT SHOCK PROTEIN; INDOLE DERIVATIVE; INITIATION FACTOR 2; MOLECULAR CHAPERONE GRP78; PROTEIN SERINE THREONINE KINASE; SULFONAMIDE;

ARTICLE; CELL PROTECTION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRESS; CELL SURVIVAL; CHEMISTRY; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; MELANOMA; METABOLISM; MUTATION; PHOSPHORYLATION; RNA INTERFERENCE; SKIN TUMOR; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; EIF-2 KINASE; ENDOPLASMIC RETICULUM STRESS; EUKARYOTIC INITIATION FACTOR-2; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEAT-SHOCK PROTEINS; HUMANS; INDOLES; MELANOMA; MUTATION; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; RNA INTERFERENCE; RNA, SMALL INTERFERING; SKIN NEOPLASMS; SULFONAMIDES;

EID: 85008174147     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.12.062     Document Type: Article

References (32)

1. [1] Harding, H.P., Zhang, Y., Zeng, H., et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11 (2003), 619–633.
2. [2] Ye, J., Kumanova, M., Hart, L.S., et al. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 29 (2010), 2082–2096.
3. [3] Harding, H.P., Zhang, Y., Bertolotti, A., et al. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol. Cell 5 (2000), 897–904.
4. [4] Nakamura, T., Furuhashi, M., Li, P., et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 140 (2010), 338–348.
5. [5] Chen, J.J., Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood 109 (2007), 2693–2699.
6. [6] Vattem, K.M., Wek, R.C., Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 11269–11274.
7. [7] Lu, P.D., Harding, H.P., Ron, D., Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J. Cell Biol. 167 (2004), 27–33.
8. [8] Beck, D., Niessner, H., Smalley, K.S., et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci. Signal., 6, 2013, ra7.
9. [9] Ma, X.H., Piao, S.F., Dey, S., et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J. Clin. Invest. 124 (2014), 1406–1417.
10. [10] Tsai, J., Lee, J.T., Wang, W., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 3041–3046.
11. [11] Davies, H., Bignell, G.R., Cox, C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
12. [12] Flaherty, K.T., Hodi, F.S., Fisher, D.E., From genes to drugs: targeted strategies for melanoma. Nat. Rev. Cancer 12 (2012), 349–361.
13. [13] Flaherty, K.T., Puzanov, I., Kim, K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363 (2010), 809–819.
14. [14] Lito, P., Rosen, N., Solit, D.B., Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 19 (2013), 1401–1409.
15. [15] Sun, C., Wang, L., Huang, S., et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508 (2014), 118–122.
16. [16] Kawaguchi, K., Murakami, T., Chmielowski, B., et al. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget 7 (2016), 71737–71743.
17. [17] Saito, S., Furuno, A., Sakurai, J., et al. Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res. 69 (2009), 4225–4234.
18. [18] Tsukumo, Y., Tsukahara, S., Furuno, A., et al. The endoplasmic reticulum-localized protein TBL2 interacts with the 60S ribosomal subunit. Biochem. Biophys. Res. Commun. 462 (2015), 383–388.
19. [19] Saito, S., Furuno, A., Sakurai, J., et al. Compound C prevents the unfolded protein response during glucose deprivation through a mechanism independent of AMPK and BMP signaling. PloS One, 7, 2012, e45845.
20. [20] Romano, P.R., Garcia-Barrio, M.T., Zhang, X., et al. Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2alpha kinases PKR and GCN2. Mol. Cell. Biol. 18 (1998), 2282–2297.
21. [21] Padyana, A.K., Qiu, H., Roll-Mecak, A., et al. Structural basis for autoinhibition and mutational activation of eukaryotic initiation factor 2alpha protein kinase GCN2. J. Biol. Chem. 280 (2005), 29289–29299.
22. [22] Berlanga, J.J., Santoyo, J., De Haro, C., Characterization of a mammalian homolog of the GCN2 eukaryotic initiation factor 2alpha kinase. Eur. J. Biochem./FEBS 265 (1999), 754–762.
23. [23] Haq, R., Shoag, J., Andreu-Perez, P., et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 23 (2013), 302–315.
24. [24] Hernandez-Davies, J.E., Tran, T.Q., Reid, M.A., et al. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J. Transl. Med., 13, 2015, 210.
25. [25] Baenke, F., Chaneton, B., Smith, M., et al. Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Mol. Oncol. 10 (2016), 73–84.
26. [26] Kilberg, M.S., Shan, J., Su, N., ATF4-dependent transcription mediates signaling of amino acid limitation. Trends Endocrinol. Metab. TEM 20 (2009), 436–443.
27. [27] Rzymski, T., Milani, M., Pike, L., et al. Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene 29 (2010), 4424–4435.
28. [28] B'Chir, W., Maurin, A.C., Carraro, V., et al. The eIF2alpha/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res. 41 (2013), 7683–7699.
29. [29] Sueda, T., Sakai, D., Kawamoto, K., et al. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells. Sci. Rep., 6, 2016, 18949.
30. [30] Hetz, C., Chevet, E., Harding, H.P., Targeting the unfolded protein response in disease. Nat. Rev. Drug Discov. 12 (2013), 703–719.
31. [31] Ma, Y., Hendershot, L.M., The role of the unfolded protein response in tumour development: friend or foe?. Nat. Rev. Cancer 4 (2004), 966–977.
32. [32] Clarke, H.J., Chambers, J.E., Liniker, E., et al. Endoplasmic reticulum stress in malignancy. Cancer Cell 25 (2014), 563–573.